Роль кверцетину у лікуванні захворювань печінки: огляд експериментальних та клінічних досліджень

Автор(и)

  • В.П. Присяжнюк д-р мед. наук, проф. кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Ukraine
  • Б.П. Сенюк канд. мед. наук, доцент кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Ukraine
  • О.В. Глубоченко канд. мед. наук, доцент кафедри пропедевтики внутрішніх хвороб, Буковинський державний медичний університет, м. Чернівці, Ukraine
  • П.В. Присяжнюк канд. хім. наук, доцент кафедри медичної та фармацевтичної хімії, Буковинський державний медичний університет, м. Чернівці, Ukraine
  • О.П. Букач канд. мед. наук, асистент кафедри внутрішньої медицини, Буковинський державний медичний університет, м. Чернівці, Ukraine

DOI:

https://doi.org/10.24061/2413-0737.XXVI.3.103.2022.16

Ключові слова:

кверцетин; неалкогольна жирова хвороба печінки; гепатит; фіброз печінки

Анотація

Науковий огляд присвячений узагальненню сучасних даних щодо ролі кверцетину в терапевтичній корекції різних захворювань печінки, з-поміж яких: неалкогольна жирова хвороба печінки, хронічний гепатит, медикаментозно-асоційовані захворювання печінки.
Мета дослідження – узагальнити сучасні наукові дані щодо властивостей кверцетину, механізму його дії та можливостей застосування цього флавоноїду в лікуванні різних захворювань печінки.
Висновки. Встановлено, що кверцетин має антиоксидантні, протизапальні, гіполіпідемічні, антистеатотичні та антифібротичні властивості. Вищезазначене свідчить про потенційну користь цього флавоноїду у терапії різних захворювань печінки, зокрема неалкогольної жирової хвороби печінки, хронічних гепатитів різної етіології та медикаментозно-асоційованих захворювань печінки.

Посилання

Andreieva ОО, Zupanets ІА, Shalamai АS. Vyvchennia hastroprotektornoi dii kombinatsii kvertsetynu ta pokhidnykh hliukozaminu na modeli etanol-prednizolonovoho urazhennia shlunka u shchuriv [Study of the gastroprotective effect of the combination of quercetin and glucosamine derivatives on the model of ethanol-prednisone gastric damage in rats]. Klinichna farmatsiia. 2009;3:32-4. (in Ukrainian).

Borikov ОIu. Protektyvnyi efekt kvertsetynu shchodo rozvytku metabolichnoho syndromu, indukovanoho vysokozhyrovoiu diietoiu u ovariektomovanykh shchuriv [Protective effect of quercetin on the development of metabolic syndrome induced by a high-fat diet in ovariectomized rats]. Problemy endokrynnoi patolohii. 2010;4:85-93. (in Ukrainian).

Ilashchuk ТО. Korvityn u likuvanni patsiientiv iz hostrym infarktom miokarda, uskladnenym hostroiu livoshlunochkovoiu nedostatnistiu [Corvitin in the treatment of patients with acute myocardial infarction complicated by acute left ventricular failure]. Bukovynskyi medychnyi visnyk. 2007;11(2):48-52. (in Ukrainian).

Kovalevska ІV. Vyznachennia fizyko-khimichnykh kharakterystyk kvertsetynu [Determination of physical and chemical characteristics of quercetin]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky. 2014;1:9-11. (in Ukrainian).

Mazur LP, Smachylo ІV, Naumova LV, Volynets КV, Krekhovska-Lepiavko ОМ, Yavorska ІV. Viddaleni rezultaty zastosuvannia antyoksydanta kvertsetynu u khvorykh na tsukrovyi diabet 2 typu z hepatozom [Long-term results of the use of the antioxidant quercetin in patients with type 2 diabetes mellitus with hepatosis]. Zbirnyk materialiv pidsumkovoi nauk.-prakt. konf. Zdobutky klinichnoi ta eksperymentalnoi medytsyny; 2012 Apr 17; Ternopil. Ternopil; 2012. p. 49. (in Ukrainian).

Posokhova КА, Zozuliak NB, Nikolaieva VV. Metabolichni porushennia pry eksperymentalnomu tsukrovomu diabeti 2 typu ta pryznachenni vodorozchynnoi formy kvertsetynu [Metabolic disorders in experimental type 2 diabetes and administration of the water-soluble form of quercetin]. Medychna ta klinichna khimiia. 2012;3:69-72. (in Ukrainian).

Prysyazhnyuk VP. Efektyvnist vykorystannia kvertsetynu u khvorykh na khronichnyi hepatyt nevirusnoho pokhodzhennia riznoho viku [The effectiveness of the use of quercetin in patients with chronic hepatitis of non-viral origin of different ages]. Halytskyi likarskyi visnyk. 2015;1:70-3. (in Ukrainian).

Prysyazhnyuk VP. Osoblyvosti vykorystannia kvertsetynu u khvorykh na nealkoholnu zhyrovu khvorobu pechinky riznykh vikovykh hrup [Features of the use of quercetin in patients with non-alcoholic fatty liver disease of different age groups]. Visnyk naukovykh doslidzhen. 2015;1:23-5. (in Ukrainian).

Prysyazhnyuk VP, Voloshyn ОІ. Klinichno-patogenetychni, vikovi, genderni, genetychni aspekty nealkoholnoi zhyrovoi khvoroby pechinky ta khronichnoho hepatytu nevirusnoho pokhodzhennia bez, a takozh z komorbidnym hipotyrozom; udoskonalennia yikh likuvannia [Clinical-pathogenetic, age, gender, genetic aspects of non-alcoholic fatty liver disease and chronic hepatitis of non-viral origin without and with comorbid hypothyroidism; improvement of their treatment]. Lvivskyi klinichnyi visnyk. 2018;3:8-23. (in Ukrainian).

Radchenko ОМ, Slaba ОR, Bek NS. Adyponektyn ta yoho rol u vnutrishnii patolohii [Adiponectin and its role in internal pathology]. Medychna hidrolohiia ta reabilitatsiia. 2012;10(1):11-8. (in Ukrainian).

Sheremeta LM. Doslidzhennia hepatoprotektornoi dii liposomalnoho kvertsetynu pry eksperymentalnomu hepatyti [Research on the hepatoprotective effect of liposomal quercetin in experimental hepatitis]. Halytskyi likarskyi visnyk. 2005;1:68-9. (in Ukrainian).

Aguirre L, Portillo MP, Hijona E, Bujanda L. Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 2014;20(23):7366-80. DOI: 10.3748/wjg.v20.i23.7366.

Bobe G, Weinstein SJ, Albanes D, Hirvonen T, Ashby J, Taylor PR, et al. Flavonoid intake and risk of pancreatic cancer in male smokers (Finland). Cancer Epidemiol Biomarkers Prev. 2008;17(3):553-62. DOI: 10.1158/1055-9965.EPI-07-2523.

Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H, et al. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD). Nutrients. 2017;9(2):96. DOI: 10.3390/nu9020096.

Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, Majano PL, Benedicto I, Rosado JA, et al. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol. 2009;50(5):872-82. DOI: 10.1016/­j.jhep.2008.12.026.

Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardio-vascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102(7):1065-74. DOI: 10.1017/S0007114509359127.

Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 2008;138(9):1615-21. DOI: 10.1093/jn/138.9.1615.

Farghali H, Kemelo MK, Canová NK. SIRT1 Modulators in Experimentally Induced Liver Injury. Oxid Med Cell Longev. 2019;2019:8765954. DOI: 10.1155/2019/8765954.

Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014;20(37):13306-24. DOI: 10.3748/wjg.v20.i37.13306.

Gori M, Giannitelli SM, Zancla A, Mozetic P, Trombetta M, Merendino N, et al. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study. Biotechnol Bioeng. 2021;118(1):142-52. DOI: 10.1002/bit.27557.

Gormaz JG, Quintremil S, Rodrigo R. Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin. Curr Top Med Chem. 2015;15(17):1735-42. DOI: 10.2174/1568026615666150427124357.

Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S. Quercetin modulates NF-kappa B and AP-1/JNK pathways to induce cell death in human hepatoma cells. Nutr Cancer. 2010;62(3):390-401. DOI: 10.1080/01635580903441196.

Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004;2(12):2138-45. DOI: 10.1111/j.1538-7836.2004.01067.x.

Jung CH, Cho I, Ahn J, Jeon TI, Ha TY. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res. 2013;27(1):139-43. DOI: 10.1002/ptr.4687.

Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, et al. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries. J Biol Chem. 2008;283(14):9424-34. DOI: 10.1074/jbc.M706571200.

Kelly GS. Quercetin. Altern Med Rev. 2011;16(2):172-94.

Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res. 2011;55(4):530-40. DOI: 10.1002/mnfr.201000392.

Kyle JA, Sharp L, Little J, Duthie GG, McNeill G. Dietary flavonoid intake and colorectal cancer: a case-control study. Br J Nutr. 2010;103(3):429-36. DOI: 10.1017/S0007114509991784.

Lee S, Lee J, Lee H, Sung J. Relative protective activities of quercetin, quercetin-3-glucoside, and rutin in alcohol-induced liver injury. J Food Biochem. 2019;43(11):e13002. DOI: 10.1111/jfbc.13002.

Li X, Jiang X, Sun J, Zhu C, Li X, Tian L, et al. Cytoprotective effects of dietary flavonoids against cadmium-induced toxicity. Ann NY Acad Sci. 2017;1398(1):5-19. DOI: 10.1111/nyas.13344.

Liu P, Lin H, Xu Y, Zhou F, Wang J, Liu J, et al. Frataxin‑mediated PINK1-Parkin-dependent mitophagy in hepatic steatosis: The protective effects of quercetin. Mol Nutr Food Res. 2018;62(16):e1800164. DOI: 10.1002/mnfr.201800164.

Liu S, Tian L, Chai G, Wen B, Wang B. Targeting heme oxygenase-1 by quercetin ameliorates alcohol-induced acute liver injury via inhibiting NLRP3 inflammasome activation. Food Funct. 2018;9(8):4184-93. DOI: 10.1039/c8fo00650d.

Mohan SK, Veeraraghavan VP, Jainu M. Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non‑alcoholic steatohepatitis. Iran J Basic Med Sci. 2015;18(8):832-6.

Montoliu C, Kosenko E, Del Olmo JA, Serra MA, Rodrigo JM, Felipo V. Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis. Liver Int. 2005;25(4):787-95. DOI: 10.1111/j.1478-3231.2005.01066.x.

Panchal SK, Poudyal H, Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. J Nutr. 2012;142(6):1026-32. DOI: 10.3945/jn.111.157263.

Porras D, Nistal E, Martínez-Flórez S, Pisonero-Vaquero S, Olcoz JL, Jover R, et al. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic Biol Med. 2017;102:188-202. DOI: 10.1016/j.freeradbiomed.2016.11.037.

Prysyazhnyuk VP, Voloshyn OI. Effects of comprehensive treatment with quercetin administration on biochemical blood parameters and pro- and anti-inflammatory cytokines in nonalcoholic fatty liver disease patients. Pharma Innovation. 2017;6(12):386-9.

Prysyazhnyuk VP. Influence of complex treatment with quercetin inclusion on cytokine profile indicators in chronic nonviral hepatitis patients. Journal of Education, Health and Sport. 2017;7(10):177-185. DOI: 10.5281/zenodo.1098531.

Saleh Al-Maamari JN, Rahmadi M, Panggono SM, Prameswari DA, Pratiwi ED, Ardianto C, et al. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol. 2021;32(4):637-44. DOI: 10.1515/jbcpp-2020-0423.

Sanjay S, Girish C, Toi PC, Bobby Z. Quercetin modulates NRF2 and NF-κB/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo. Can J Physiol Pharmacol. 2021;99(9):952-63. DOI: 10.1139/cjpp-2021-0008.

Sotiropoulou M, Katsaros I, Vailas M, Lidoriki I, Papatheodoridis GV, Kostomitsopoulos NG, et al. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi J Gastroenterol. 2021;27(6):319-30. DOI: 10.4103/sjg.sjg_249_21.

Surapaneni KM, Priya VV, Mallika J. Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). Eur Rev Med Pharm Sci. 2014;18(18):2736-41.

Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32(6):945-50. DOI: 10.1111/j.1478-3231.2011.02753.x.

Vicente-Sánchez C, Egido J, Sánchez-González PD, Pérez-Barriocanal F, López-Novoa JM, Morales AI. Effect of the flavonoid quercetin on cadmium-induced hepatotoxicity. Food Chem Toxicol. 2008;46(6):2279-87. DOI: 10.1016/j.fct.2008.03.009.

Vidyashankar S, Sandeep Varma R, Patki PS. Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol In Vitro. 2013;27(2):945-53. DOI: 10.1016/j.tiv.2013.01.014.

Wan Y, Tang MH, Chen XC, Chen LJ, Wei YQ, Wang YS. Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A. Braz J Med Biol Res. 2014;47(8):655-61. DOI: 10.1590/1414-431x20143704.

Wilson RT, Wang J, Chinchilli V, Richie JP, Virtamo J, Moore LE, et al. Fish, vitamin D, and flavonoids in relation to renal cell cancer among smokers. Am J Epidemiol. 2009;170(6):717-29. DOI: 10.1093/aje/kwp178.

Wu L, Wang C, Li J, Li S, Feng J, Liu T, et al. Hepatoprotective effect of quercetin via TRAF6/JNK pathway in acute hepatitis. Biomed Pharmacother. 2017;96:1137-46. DOI: 10.1016/j.biopha.2017.11.109.

Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother Res. 2019;33(12):3140-52. DOI: 10.1002/ptr.6486.

Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem Toxicol. 2013;52:53-60. DOI: 10.1016/j.fct.2012.10.030.

Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M, et al. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore). 2017;96(18):e6712. DOI: 10.1097/MD.0000000000006712.

Zhang X, Li Y, Wei X, Hou Y, Jia S, Li S, et al. Metabolomics analysis of the effects of quercetin on hepatotoxicity induced by acrylamide exposure in rats. Free Radic Res. 2021;55(7):831-41. DOI: 10.1080/10715762.2021.1950705.

Zhang Y, Gu M, Cai W, Yu L, Feng L, Zhang L, et al. Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci Rep. 2016;6:19288. DOI: 10.1038/srep19288.

Zhang Y, Qu X, Gao H, Zhai J, Tao L, Sun J, et al. Quercetin attenuates NLRP3 inflammasome activation and apoptosis to protect INH-induced liver injury via regulating SIRT1 pathway. Int Immunopharmacol. 2020;85:106634. DOI: 10.1016/j.intimp.2020.106634.

Zhao X, Wang J, Deng Y, Liao L, Zhou M, Peng C, et al. Quercetin as a protective agent for liver diseases: A comprehensive descriptive review of the molecular mechanism. Phytother Res. 2021 Sep;35(9):4727-47. DOI: 10.1002/ptr.7104.

Zhu X, Xiong T, Liu P, Guo X, Xiao L, Zhou F, et al. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem Toxicol. 2018;114:52-60. DOI: 10.1016/j.fct.2018.02.019.

##submission.downloads##

Опубліковано

2022-10-27

Номер

Розділ

НАУКОВІ ОГЛЯДИ